Breast cancer

15 March 2006

Discovery to pay for cancer drug

Discovery Health has announced that they will fund the breast cancer drug Herceptin for a full year for members who are not eligible for the short course protocol.

0
Discovery Health has announced that they will fund the breast cancer drug Herceptin for a full year for members who are not eligible for the short course protocol.

The genetic profile of a woman with breast cancer can determine her treatment. Women diagnosed with breast cancer and who carry the HER-2/neu gene react very well to certain types of treatment, such as Herceptin, while women with other genes react better to other treatment regimes, according to Health24.

Genetic testing can determine which women, who have been diagnosed with breast cancer, carry the HER-2/neu gene.

Last week Discovery announced that they would fund the drug for the nine-week short course protocol, a decision which followed new treatment guidelines issued by the South African oncology Consortium (SAOC) that said it is reasonable to provide a nine-week course of herceptin where there are financial constraints prohibiting a year-long course of the drug.

However, it has recently been clarified that this treatment regimen is not appropriate for patients commencing the use of Herceptin more than three months (but less than 11 months) after surgery. A one-year regimen is recommended by the SAOC in these cases, according to a press release from Discovery.

"To ensure consistency and equity for current members, who are not eligible for the “short-course” protocol, because more than three months have elapsed since surgery, Herceptin will be covered for the one-year regimen in full for these members only, based on the treatment plan prescribed by their oncologists," the press release said.

“We are pleased to have been able to find a solution which provides all Discovery Health members currently requiring access to Herceptin, as well as members who may require access in the future, full and comprehensive coverage,” said Adrian Gore, CEO of Discovery. – (Health24)

Sources: Press release from Discovery Health and Health24.com

Read more:
Green light for Herceptin, Breast Centre

March 2006

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules